Lung cancer is one of the most common and deadly types of cancer worldwide. Non-small cell lung cancer accounts for 85% of all lung cancers, and the survival rate of lung cancer patients is closely related to the time of diagnosis, with higher survival rates associated with early detection. However, early-stage lung cancer lacks specific clinical features, and most lung cancer patients do not exhibit obvious symptoms in the early stages of the disease. As a result, many patients are diagnosed in the intermediate or late stages. Pulmonary nodules are early manifestations of lung cancer, but not all nodules indicate lung cancer. With the advent of LDCT, more and more lung nodules are being detected, but distinguishing between benign and malignant nodules remains challenging. Therefore, there is an urgent need to develop blood-based biomarkers as more effective diagnostic tools for precise diagnosis of lung cancer in high-risk individuals.

Ruifei Yang, Feixue Feng, Yanxia Ma. Research Progress on MicroRNA in Early Diagnosis of Lung Cancer. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 9: 36-41. https://doi.org/10.25236/IJFM.2023.050907.

[1] Abu Rous F, Singhi EK, Sridhar A, Faisal MS, Desai A. Lung Cancer Treatment Advances in 2022 [J]. Cancer Invest, 2023, 41(1):12-24. 

[2] Hu C, Meiners S, Lukas C, Stathopoulos GT, Chen J. Role of exosomal microRNAs in lung cancer biology and clinical applications [J]. Cell Prolif, 2020, 53(6):e12828. 

[3] Nasim F, Sabath BF, Eapen GA. Lung Cancer [J]. Med Clin North Am, 2019, 103(3):463-473. doi: 10. 1016/j. mcna. 2018. 12. 006. 

[4] Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer [J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(10):1563-1579. doi: 10. 1158/1055-9965. EPI-19-0221. PMID: 31575553; PMCID: PMC6777859. 

[5] Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics [J]. Crit Rev Oncol Hematol, 2016, 98:12-23. doi: 10. 1016/j. critrevonc. 2015. 10. 003. Epub 2015 Oct 8. PMID: 26481951. 

[6] Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? [J]. Cancer Metastasis Rev, 2009, 28(3-4):369-378. 

[7] Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer [J]. Nat Rev Cancer, 2015, 15(6):321-333.

[8] Hayes J, Peruzzi P P, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy [J]. TRENDS IN MOLECULAR MEDICINE, 2014, 20(8):460-469. 

[9] Sozzi G, Boeri M, Rossi M, et al. Clinical Utility of a Plasma-Based miRNA Signature Classifier Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial Study [J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2014, 32(8):768. 

[10] Shen J, Todd N W, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer [J]. Laboratory investigation; a journal of technical methods and pathology, 2011, 91(4):579. 

[11] Liu J, Jiang Z, Zhou S, et al. Serum microRNA expression profiling identifies miR-27a as a potential diagnostic biomarker in patients with early-stage non-small cell lung cancer [J]. Transl Lung Cancer Res, 2020, 9(4):1302-1313. 

[12] Pastorino U, Silva M, Sestini S, et al. Lung cancer biomarkers: State of the art [J]. Front Biosci (Landmark Ed), 2020, 25:1211-1240. 

[13] Hsu YL, Hung JY, Chang WA, et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1 [J]. Oncogene, 2017, 36(34):4929-4942. 

[14] Han L, Liu F, Li M, et al. MicroRNA-145 promotes the sensitivity of non-small cell lung cancer cells to MET inhibitors via the IRS1/PI3K/Akt pathway [J]. Cell Biol Int, 2020, 44(5):1176-1187. 

[15] Liu W, Li Z, Xu H, et al. miR-144-3p suppresses the aggressive phenotypes of lung adenocarcinoma by targeting PBX3 [J]. Cancer Cell Int, 2020, 20:86.